Jefferies Reiterates Hikma Pharmaceuticals PLC

Jefferies reiterated a 'Buy' rating for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on November 7, 2025, setting an average one-year price target of $66.69, which implies a 33.11% upside from its $50.10 closing price. This positive analyst outlook comes despite projected annual revenue decreasing by 10.45% to $2,880MM, with non-GAAP EPS estimated at $2.12. Institutional sentiment appears mixed, as total shares owned by institutions decreased by 11.43% to 16K, even though the average portfolio weight dedicated to HKMPY increased by 4.90% among reporting funds.

Analysis

Jefferies reiterated a "Buy" recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on November 7, 2025, setting an average one-year price target of $66.69. This target suggests a substantial 33.11% upside from the latest closing price of $50.10, indicating strong conviction from the analyst despite a broad target range from $53.42 to $80.28.

This positive analyst outlook contrasts with the company's projected financial performance, which includes an anticipated 10.45% decrease in annual revenue to $2,880 million. However, the projected annual non-GAAP EPS stands at $2.12, suggesting potential profitability resilience or cost management despite top-line pressures.

Institutional investor sentiment appears mixed, with total shares owned by institutions decreasing by 11.43% to 16K over the last three months. Conversely, the average portfolio weight dedicated to HKMPY among reporting funds increased by 4.90% to 1.14%, indicating that while some institutions reduced holdings, those maintaining positions allocated a larger proportion of their portfolios to the stock. PMEFX, a specific fund, decreased its HKMPY allocation by 4.90% and reduced its share count by 12.90%.

Key Decisions for Investors

• Investors should consider the Jefferies "Buy" rating and 33.11% price target upside as a positive signal, but balance it against the projected 10.45% decline in annual revenue.
• It is prudent to monitor future institutional ownership reports for clearer sentiment, given the current mixed signals of decreased total shares but increased average portfolio weight.
• A deeper dive into the company's fundamental drivers, particularly the source of the revenue decline and the sustainability of the $2.12 non-GAAP EPS, is warranted before making significant investment decisions.